我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去）

+ I6 k  F8 U' A8 x
/ Q& q( C7 O" C9 j- D' K9 `祝老马老师新年快乐！今天看了你的，《肺癌骨转移的双膦酸盐治疗》这篇文章，想有个问题请教你：我父亲由于手术前未确定病灶的良性还是恶性，所以先行手术，确定恶性后，手术后补做了骨扫描，结论：右侧股骨颈骨代谢增高灶，建议进一步检查。三个月后核磁复查：右侧髂骨、股骨头、股骨颈见结节状异常信号T1WI低信号、T2WI高信号。左侧股骨头见斑点状T2W1高信号影，髋臼及关节间隙如常，左侧髋关节囊见少量积液。结果诊断：右侧髂骨、股骨颈及两侧股骨头异常信号。问过好多医生，未能诊断是否骨转移。术后至今已7月多，一直未疼痛，碱性磷酸酶也正常，请问老师骨转移的可能性大吗？

我觉得骨转移可能性大，建议再做个核磁，看看有什么变化没有。
( b+ z: H- F  M确定后可以打骨转针。
肿瘤指标有没有检查？

谢谢马老师这么快回复;肿瘤指标有检查,CEA手术前5.6,手术后2.7,总共四次培美曲塞+顺伯,前三次后CEA都在2.7左右,第四次后4.22,现在3.6,现在跟正常人一模一样,体重回升3公斤,正常上班,真想现在的好时光能长点,再长点.

LUNG CANCER HARB ORING HER2 MUTATION :EPIDE MIOLOGI CAL CHARACTE RISTICS AND
$ ^0 m% U( Y. t4 sTHERAPE UTIC PERSPECTIVES
J. Mazieres, S. Peters
2 T  Q1 s- T7 R5 b! _6 UIntroduction: HER2 oncogene is a memb er of the EGFR family, encoding atransmembrane receptor that drives and regulates cell proliferation. HER2 mutations are identified in about 2% of non small cell lung cancer (NSCLC) , mainly located in exon 20, and appear to be critical for lung cancer carcinogenesis . Very scarce data are available to define a clinical profile of the patients harboring HER2 mutated NSCLC. We aimed to study clinic opatholog ical characteristics an d therapeutic
+ L; m+ d. |& a( S# w# _outcomes of patients harboring HER2 mutation in a large European series. Result s:We retrospec tively ide ntified 46 NSCLC patients diagn osed with HER2 exon 20 mut ation. HER2 mutation was mainly exclusive as only one concomitan t KRas mutation was des cribed. Our population was characterized by a median age of 60 yr (31 to 86 yr), a high proportion of women (30 vs. 16 men, 65% ), and of never smokers (24, 52%). All tumors were adenoc arcinomas (two with lepidic features). Half of the patients had stage IV dise ase at the time of diagnosis. HER2 targeted
; U' w, k& |* F. |0 ^- X5 X# K  I/ Vtreatment was delivered after convention al chemothe rapy. A total of 20 anti-Her2
treatments were eval uable. We observed 4 progressive dise ases, 7 disease stabilizations
( f7 k1 H7 U4 yand 9 partial resp onses according to RECIST 1.1 (overall response rate ORR = 45% ;
$ Q3 N6 Q4 a  O) Y) ?* }, _5 r! ^3 Jdisease control rate DCR = 80%). Specifica lly, we obse rved a DCR of 92% for
: L9 S5 {! C5 O- X3 d6 Strastuzum ab-based therapie s (n = 14), 100 % for afatinib (n = 3) but no response to
6 E8 r( t4 I8 \$ @lapatinib (n = 2) and to a multiTKI (n = 1). Median survival was of 68.2 months and
22.9 months for respectively early stage and stag e IV patients.
Conclusion: This study, the largest to date dedic ated to HER2 mutated NSCLC,
reinforces the importance of an HER2 screening strategy in lung adenoc arcinomas .
# M# a! j$ t; E3 uHER2-target ed drugs shou ld be tested further, ide ally withi n large collaborative
/ g+ M) t/ o1 V1 J3 C* z& O$ t" cclinicaltrials.

老马：你好！一口气看完你的帖子，受益非浅，现在有问题想向你请教一下
0 H6 u* I* x: j0 B5 h   最近非常纠结于我爸爸的下一步治疗情况，想请教一下您，麻烦帮我看看他的CEA算敏感的吗？为什么最近CEA变化和肿瘤大小变化怎么不符合了呢？目前CT象征肿瘤算不算增大了呢？是否能继续空窗或者用靶向？以下是治疗帖。http://www.yuaigongwu.com/thread-8252-1-1.html
5 K8 ?9 d0 R  B1 X0 Q0 T) \, f# \  t

谢谢你这么快给我回复，骨转针已打了7针，是否要继续？
  ]. y4 F9 d1 z! v9 dCEA为什么会突然变得不敏感呢？再次感谢！

! U. S7 b2 a5 ]! I

经常上来，但是第一次注册。 父也是肺鳞癌！

向老马请教，病人的淋巴细胞亚群检测是不是很重要？

/ F: [9 Z; G/ C3 R+ Z因这个项目检查要自费
. N/ `" ~; U& F{:soso_e117:}
$ r% U3 R) P7 n1 ^$ L所以......
下周去检查
谢谢老马！